Educational information only. This site does not provide medical advice. Read full disclaimer
    PepTracker Pro
    Open the App
    Research-only content. This page is for educational purposes and does not constitute medical advice. Read full disclaimer →

    Epithalon

    Low Evidence

    A tetrapeptide studied for its potential to activate telomerase and influence biological aging markers.

    AliasesEpitalon+2 more
    EvidenceLow Evidence
    Last Updated 2026-05-10
    Reading Time 2 min

    What It Is

    Epithalon (also spelled Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the natural peptide epithalamin, produced by the pineal gland. Research, primarily from Russian laboratories, has explored its potential to activate telomerase, the enzyme responsible for maintaining telomere length. A 2025 study published in PMC confirmed that Epitalon increases telomere length in multiple human cell lines through both telomerase upregulation and alternative lengthening of telomeres (ALT) activity — providing important independent confirmation of Khavinson's original findings. Epithalon is now understood to act on five hallmarks of aging: telomere maintenance, epigenetic regulation, oxidative stress resilience, immune recalibration, and circadian rhythm restoration. In 2026, Epithalon is increasingly studied as part of longevity combination protocols alongside NAD+ and MOTS-c, with researchers targeting multiple aging pathways simultaneously — telomere maintenance (Epithalon), cellular energy (NAD+), and metabolic fitness (MOTS-c). Epitalon is scheduled for PCAC review on July 24, 2026, alongside Emideltide and Semax, to evaluate whether it can be legally compounded under section 503A. Public comments via docket FDA-2025-N-6895 are accepted until July 22, 2026.

    Also known as: Epitalon, Epithalone, AEDG peptide

    Regulatory Status

    Category 1 — Bulk Compounding (PCAC review July 24, 2026)

    Moved from Category 2 back to Category 1 per HHS announcement February 27, 2026. FDA PCAC will review Epitalon (free base and acetate) on July 24, 2026 for potential 503A Bulks List inclusion. Public comment docket FDA-2025-N-6895 open until July 22, 2026.

    Effective: February 2026

    View FDA Source

    Evidence Snapshot

    Low Evidence
    Low
    Medium
    High
    Study Type Model Outcome Link
    In vitro (2025) Multiple human cell lines — telomere length assays Confirmed telomere lengthening through both telomerase upregulation and ALT activity — independent replication of original Khavinson findings Source
    Animal (rat) Aging rodent lifespan study (Khavinson lab) Extended mean lifespan; reduced spontaneous tumor incidence; improved immune markers Source

    Commonly Discussed Benefits

    Safety & Cautions

    • Most research from a single laboratory group
    • Limited independent replication of results
    • No human clinical trials registered in Western databases
    • Claims about lifespan extension remain unverified in humans

    Comparisons

    See how Epithalon compares to related peptides:

    Calculator Tools

    Use our research tools to explore dosing and reconstitution data:

    Citations

    1. [1] Khavinson VK. et al. — Epithalon peptide induces telomerase activity. Bull Exp Biol Med. 2003 PubMed
    2. [2] Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity — PMC 2025 PubMed

    Continue Your Research

    Track your research notes and set reminders in the companion app.

    Related Peptides

    GHK-Cu

    High Evidence

    A naturally occurring copper-binding peptide studied for skin regeneration, wound healing, and anti-aging effects.

    Thymosin Alpha-1

    High Evidence

    A thymic peptide approved in some countries for immune modulation, studied for viral infections and cancer adjunct therapy.

    MOTS-c

    Low Evidence

    A mitochondrial-derived peptide studied for metabolic regulation, exercise mimetic effects, and longevity.

    SS-31

    High Evidence

    A mitochondria-targeted peptide FDA-approved as FORZINITY (elamipretide) for Barth syndrome in September 2025 — the first FDA-approved mitochondrial-targeted therapeutic.

    FOXO4-DRI

    Low Evidence

    A senolytic peptide designed to selectively clear senescent cells by disrupting FOXO4-p53 interaction.